Evidence map›Paper›PMID 29551924›Full record

ArticleSaudi journal of biological sciences2017

Involvement of erbB4 and tumor marker genes in renal carcinoma regulatory network.

Xiaofu Wang, Bin Hao, Changbao Xu, Xinghua Zhao, Changwei Liu, Xiaohan Chu, Yuan Lv, Yongli Zhao, Shengwei Zhang, Pengsen Wang and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Saudi journal of biological sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Xiaofu WangThe Second Affiliated Hospital of Zhengzhou University (Institute of Urinary Surgery of Zhengzhou University; the Calculosis Diagnostic and Therapeutic Center of Henan Province), China.
Bin HaoThe Second Affiliated Hospital of Zhengzhou University (Institute of Urinary Surgery of Zhengzhou University; the Calculosis Diagnostic and Therapeutic Center of Henan Province), China.
Changbao XuThe Second Affiliated Hospital of Zhengzhou University (Institute of Urinary Surgery of Zhengzhou University; the Calculosis Diagnostic and Therapeutic Center of Henan Province), China.
Xinghua ZhaoThe Second Affiliated Hospital of Zhengzhou University (Institute of Urinary Surgery of Zhengzhou University; the Calculosis Diagnostic and Therapeutic Center of Henan Province), China.
Changwei LiuThe Second Affiliated Hospital of Zhengzhou University (Institute of Urinary Surgery of Zhengzhou University; the Calculosis Diagnostic and Therapeutic Center of Henan Province), China.
Xiaohan ChuThe Second Affiliated Hospital of Zhengzhou University (Institute of Urinary Surgery of Zhengzhou University; the Calculosis Diagnostic and Therapeutic Center of Henan Province), China.
Yuan LvThe Second Affiliated Hospital of Zhengzhou University (Institute of Urinary Surgery of Zhengzhou University; the Calculosis Diagnostic and Therapeutic Center of Henan Province), China.
Yongli ZhaoThe Second Affiliated Hospital of Zhengzhou University (Institute of Urinary Surgery of Zhengzhou University; the Calculosis Diagnostic and Therapeutic Center of Henan Province), China.
Shengwei ZhangThe Second Affiliated Hospital of Zhengzhou University (Institute of Urinary Surgery of Zhengzhou University; the Calculosis Diagnostic and Therapeutic Center of Henan Province), China.
Pengsen WangThe Second Affiliated Hospital of Zhengzhou University (Institute of Urinary Surgery of Zhengzhou University; the Calculosis Diagnostic and Therapeutic Center of Henan Province), China.
Youzhi WangThe Second Affiliated Hospital of Zhengzhou University (Institute of Urinary Surgery of Zhengzhou University; the Calculosis Diagnostic and Therapeutic Center of Henan Province), China.
Second Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRenal carcinoma is a common urologic tumor, and there is no ideal tumor marker for clinical diagnosis except for imaging diagnosis. This study aims to screen the serum tumor markers closely related with the benign and malignant of renal carcinoma out and chart out the regulatory network that involves renal carcinoma-related genes.

methodsBased on 96 pathologically diagnosed renal cancer patients, factors strongly linked to renal carcinoma character were selected using Fisher discriminant analysis. The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases were utilized to manipulate function annotation of erbB4 and the selected genes and pathway analysis.

resultsFour essential tumor markers CYFRA21-1, CA125, VHL and HIF-1β were successfully screened out. Using GO and KEGG databases, the regulatory network of renal cancer cell escaping apoptosis was charted out on the basis of erbB4 signaling pathway.

conclusionSerum tumor marker genes play a certain part in the genesis and development of renal carcinoma. We preliminarily illustrated the molecular mechanism of these markers to predict tumor, laying a foundation for further exploration in renal carcinoma.

Indexed as

erbb4Regulatory networkRenal carcinomaTumor marker

Identifiers

PMID29551924
PMCPMC5851941
OpenAlexW2767858953

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.